Shares of Edap Tms SA (NASDAQ:EDAP) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus price target of $6.50 for the company and are expecting that the company will post $0.01 EPS for the current quarter, according to Zacks. Zacks has also given Edap Tms an industry rank of 104 out of 256 based on the ratings given to its competitors.
Several analysts recently weighed in on EDAP shares. ValuEngine upgraded YY from a “sell” rating to a “hold” rating in a research report on Friday, June 7th. HC Wainwright set a $4.00 price objective on Uranium Energy and gave the stock a “buy” rating in a research report on Tuesday, June 11th. Zacks Investment Research upgraded Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a research report on Monday, July 8th. Finally, TheStreet downgraded Timkensteel from a “c-” rating to a “d+” rating in a research report on Monday, June 17th.
Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings data on Wednesday, May 15th. The medical equipment provider reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. Edap Tms had a negative return on equity of 1.13% and a negative net margin of 0.36%. The business had revenue of $11.50 million during the quarter, compared to the consensus estimate of $13.25 million. Analysts expect that Edap Tms will post 0.08 EPS for the current fiscal year.
A hedge fund recently raised its stake in Edap Tms stock. Fosun International Ltd increased its holdings in shares of Edap Tms SA (NASDAQ:EDAP) by 45.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 363,485 shares of the medical equipment provider’s stock after buying an additional 114,342 shares during the quarter. Fosun International Ltd owned 1.25% of Edap Tms worth $1,072,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.31% of the company’s stock.
About Edap Tms
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
See Also: Quiet Period
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.